GRAFAPEX (treosulfan) for Injection Receives CMS Approval of New Technology Add-On Payment (NTAP) for Eligible Cases in CMS's Fiscal Year 2026 @MedexusInc #SpecialtyPharma #Chemicals #Pharmaceutical #Biotechnology #HealthCare #Medical #Pharmaceuticals #AnnualResults #OTC #OTCMarkets #OTCStocks #TSX #Investing
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - August 5, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that the US Centers for Medicare & Medicaid Services (CMS) has approved New Technology Add-On Payment (NTAP) reimbursement for eligible cases involving the use of GRAFAPEX™ (treosulfan) for Injection for CMS's fiscal year 2026, which runs from October 1, 2025 to September 30, 2026.*The NTAP program is designed to provide temporary supplemental...
http://dlvr.it/TMJkyM
http://dlvr.it/TMJkyM
Comments
Post a Comment